﻿<?xml version="1.0" encoding="utf-8"?><!--RSS Generated by www.ashp.org on Fri, 03 Feb 2012 22:18:42--><rss version="2.0"><channel><title>ASHP Health-System Pharmacy News</title><link>http://www.ashp.org/menu/News/PharmacyNews.aspx</link><description>ASHP Health-System Pharmacy News</description><language>en-us</language><copyright>Copyright2012 ASHP</copyright><docs>http://cyber.law.harvard.edu/rss/</docs><lastBuildDate>Fri, 03 Feb 2012 22:18:42</lastBuildDate><image><url>http://www.ashp.org/images/ashprss.gif</url><title>ASHP</title><link>http://www.ashp.org/</link><width>57</width><height>34</height></image><item><title><![CDATA[Pfizer Recalls 28 Lots of Oral Contraceptives]]></title><link>http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3675</link><description><![CDATA[Pfizer on January 31 announced the recall of 28 lots of oral contraceptive tablets because of problems with the packaging configurations.]]></description><category>ASHP News</category><author>Kate Traynor</author><guid isPermaLink="false">http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3675</guid><pubDate>Wed, 01 Feb 2012</pubDate></item><item><title><![CDATA[Medical Food Company Recalls Renastart]]></title><link>http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3674</link><description><![CDATA[Not all cans bearing the label "Renastart" and marked "Batch No. 12832" on the bottom contain that medical food, which is intended specifically for patients 1 year or older with renal failure, Vitaflo USA LLC announced Monday. In following up on a customer's complaint, the company discovered that a medical food other than Renastart may have been labeled as such.]]></description><category>ASHP News</category><author>Cheryl A. Thompson</author><guid isPermaLink="false">http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3674</guid><pubDate>Tue, 31 Jan 2012</pubDate></item><item><title><![CDATA[Ivacaftor Approved for Cystic Fibrosis]]></title><link>http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3673</link><description><![CDATA[FDA today announced the approval of ivacaftor, an oral therapy that the agency called a breakthrough in personalized medicine for people with a rare form of cystic fibrosis (CF).]]></description><category>ASHP News</category><author>Kate Traynor</author><guid isPermaLink="false">http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3673</guid><pubDate>Tue, 31 Jan 2012</pubDate></item><item><title><![CDATA[FDA Approves First Drug Treatment for Metastatic Basal Cell Carcinoma]]></title><link>http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3672</link><description><![CDATA[Genentech and FDA today announced the approval of vismodegib, or Erivedge, for the treatment of adults with locally advanced basal cell cancer who are not candidates for surgery or radiotherapy or whose cancer has metastasized.]]></description><category>ASHP News</category><author>Cheryl A. Thompson</author><guid isPermaLink="false">http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3672</guid><pubDate>Mon, 30 Jan 2012</pubDate></item><item><title><![CDATA[Cephalon Recalls Bendamustine Lot TB30111]]></title><link>http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3671</link><description><![CDATA[Cephalon Inc. is recalling Treanda lot TB30111, containing bendamustine hydrochloride, because glass fragments were found in one of the vials, according to a press release circulated today by FDA.]]></description><category>ASHP News</category><author>Cheryl A. Thompson</author><guid isPermaLink="false">http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3671</guid><pubDate>Fri, 27 Jan 2012</pubDate></item><item><title><![CDATA[Axitinib Approved for Advanced Kidney Cancer]]></title><link>http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3670</link><description><![CDATA[FDA on January 27 announced the approval of axitinib as second-line therapy in patients with advanced renal cell carcinoma that has not responded to previously administered systemic agents.]]></description><category>ASHP News</category><author>Kate Traynor</author><guid isPermaLink="false">http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3670</guid><pubDate>Fri, 27 Jan 2012</pubDate></item><item><title><![CDATA[Remote Technician Supervision Up and Running in Kansas]]></title><link>http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3668</link><description><![CDATA[How many onsite pharmacists does it take to oversee the dispensing of medications and refilling of automated dispensing cabinets in a Kansas hospital?]]></description><category>ASHP News</category><author>Kate Traynor</author><guid isPermaLink="false">http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3668</guid><pubDate>Fri, 27 Jan 2012</pubDate></item><item><title><![CDATA[Medication Guides Leave Their REMS Programs Behind]]></title><link>http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3667</link><description><![CDATA[With little fanfare, FDA has been following up on a plan to free manufacturers from the need to implement risk evaluation and mitigation strategy (REMS) programs that consist solely of a medication guide.]]></description><category>ASHP News</category><author>Kate Traynor</author><guid isPermaLink="false">http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3667</guid><pubDate>Fri, 27 Jan 2012</pubDate></item><item><title><![CDATA[One IVIG Mystery Solved, Another Demands Vigilance]]></title><link>http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3666</link><description><![CDATA[The mysterious link between one manufacturer&#8217;s intravenous immune globulin (IVIG) product and an unusual rate of thrombotic and thromboembolic events is now known—too much coagulation factor XIa. But the company&#8217;s resolution of that issue does not mean pharmacists can relax their efforts to minimize the risk of adverse events related to the manufacture of IVIG products, said two experts.]]></description><category>AJHP</category><author>Cheryl A. Thompson</author><guid isPermaLink="false">http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3666</guid><pubDate>Fri, 27 Jan 2012</pubDate></item><item><title><![CDATA[New Gel OK'd for Treatment of Precancerous Skin Lesions]]></title><link>http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3665</link><description><![CDATA[FDA has approved the marketing of ingenol mebutate gel, or Picato, for the topical treatment of actinic keratosis, Leo Pharma Inc. announced today.]]></description><category>ASHP News</category><author>Cheryl A. Thompson</author><guid isPermaLink="false">http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&amp;Type=Rss&amp;Id=3665</guid><pubDate>Wed, 25 Jan 2012</pubDate></item></channel></rss>
